JNJ Stock Analysis: Buy, Sell, or Hold?
JNJ - Johnson & Johnson
$253.61
-2.75 (-1.07%)
▼
5d:
-4.64%
30d:
-3.59%
90d:
+11.63%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Oct 13, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.0/10
Get Alerted When JNJ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: JNJ shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: JNJ shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$337.77
Based on 7.1% avg growth
INTRINSIC VALUE TODAY
$209.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JNJ is currently trading at $253.60, which is considered slightly low relative to its 30-day fair value range of $250.96 to $262.92. The stock's valuation (Forward PE: 20.0) is in line with its historical norms (18.7). At these levels, the market is pricing in 2.3% annual earnings growth.
Technical Outlook: Technically, JNJ is in a strong uptrend. Immediate support is located at $245.49, while resistance sits at $274.90.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JNJ is in a strong uptrend. Immediate support is located at $245.49, while resistance sits at $274.90.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$250.96 -
$262.92
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($270.59)
- BULLISH: Expecting earnings turnaround to 2.3% growth with 6.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$250.96 -
$262.92
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$245.49
Resistance Level
$274.90
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.98
Wall Street Target
$270.59
(+5.6%)
Revenue Growth (YoY)
6.6%
Earnings Growth (YoY)
-0.9%
Profit Margin
21.5%
Valuation Premium vs History
+2.3% premium
PE vs Historical
20.0 vs 18.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.3%
(market-implied from PE analysis)
1-Year Target
$262.25
(+2%)
2-Year Target
$268.28
(+5%)
3-Year Target
$274.45
(+7%)
3-Yr Target (if PE normalizes)
(PE: 20→19)
PE COMPRESSION
$256.90
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 10.2%)
$355.65
(+39%)
Base:
(SPY PE: 20.0, Growth: 10.2%)
$342.74
(+34%)
Bear:
(PE: 17.0, Growth: 10.2%)
$291.33
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 30.78 | Current EPS (TTM): $8.31
Bull Case
$434.52
(+70%)
Analyst growth 54.4%, PE expands to 33.9
Base Case
$395.02
(+54%)
Market implied 54.4%, PE stable at 30.8
Bear Case
$173.96
(-32%)
Severe decline -20.0%, PE contracts to 26.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 2:29 PM ET
Data refreshes hourly during market hours. Next update: 3:29 PM
Data refreshes hourly during market hours. Next update: 3:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JNJ showing a specific setup today?
Insider Activity (6 Months)
2
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas H. Kean, Jr.
SELL
2026-03-26
John Boozman
SELL
2026-03-19
Richard McCormick
SELL
2026-03-19
Featured in Portfolios
JNJ is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
Advanced JNJ Option Strategies
Professional options setups generated by AI based on today's JNJ price and gamma walls.
